Company to Provide Updates on Phase 2 Clinical Trials for COVID-19 Vaccine and Immuno-oncology/Gedeptin^®

ATLANTA, GA - (NewMediaWire) - May 29, 2024 - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company specializing in developing human vaccines and cancer immunotherapies, today announced that its Chairman & CEO, David Dodd, will present at the BIO International Convention 2024 being held June 3-6 in San Diego.

Details of the presentation are as follows:

Date:               June 3, 2024

Time:              3:45 p.m. Pacific Time

Location:         San Diego Convention Center, Company Presentation Theater 2

Format:           Company Presentation & One-On-One Meetings

Registration:   Click Here

During the conference, members of the GeoVax management team will host one-on-one meetings with registered attendees to explore collaborative and strategic opportunities around the company’s development portfolio including GEO-CM04S1, a multi-antigenic, next generation COVID-19 vaccine currently being investigated in three Phase 2 studies and Gedeptin^®, an adenovirus-vectored bacterial purine phosphorylase designed to locally activate a systemically administered chemotherapeutic prodrug which is currently in a Phase 2 study for the treatment of advanced Head and Neck (H&N) cancers.  Individuals interested in meeting with GeoVax are encouraged to reach out to the Company through the scheduling platform available on the conference website or by contacting Company management directly.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin^®, which recently completed enrollment in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation COVID-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.